Encouraging preliminary data from Curasight’s phase I glioblastoma trial are helping to shape the next stage of development. The company has submitted a protocol amendment designed to strengthen the clinical data set and generate additional information to inform future studies. A directed share issue of approximately DKK 20 million funds the path to that readout. BioStock contacted CEO Ulrich Krasilnikoff for a comment.
Read the full interview at biostock.se:
Curasight: Letting the data guide uTREAT development
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/